Cell cycle kinases as therapeutic targets for cancer (Q28250447)

Nature Reviews Drug Discovery

Europe PubMed Central

title

Cell cycle kinases as therapeutic targets for cancer (English)

0 references

Antonio Giordano

2

0 references

author name string

Silvia Lapenna

series ordinal

1

0 references

language of work or name

English

0 references

publication date

July 2009

0 references

published in

0 references

volume

8

0 references

issue

7

0 references

page(s)

547-66

0 references

cites work

The retinoblastoma protein and cell cycle control

1 reference

RB and cell cycle progression

31 March 2020

1 reference

Cdk1 is sufficient to drive the mammalian cell cycle

31 March 2020

1 reference

Aurora-A: the maker and breaker of spindle poles

31 March 2020

1 reference

Polo-like kinases: conservation and divergence in their functions and regulation

31 March 2020

1 reference

Cell cycle, CDKs and cancer: a changing paradigm

31 March 2020

1 reference

On the road to cancer: aneuploidy and the mitotic checkpoint

31 March 2020

1 reference

Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint.

31 March 2020

1 reference

Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells

31 March 2020

1 reference

Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells.

31 March 2020

1 reference

Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases

31 March 2020

1 reference

Cyclin-dependent kinase pathways as targets for cancer treatment

31 March 2020

1 reference

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

31 March 2020

1 reference

Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer

31 March 2020

1 reference

The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells

31 March 2020

1 reference

A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties

31 March 2020

1 reference

Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio

31 March 2020

1 reference

In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.

31 March 2020

1 reference

P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.

31 March 2020

1 reference

Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

31 March 2020

1 reference

In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials

31 March 2020

1 reference

Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709.

31 March 2020

1 reference

The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model

31 March 2020

1 reference

In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)

31 March 2020

1 reference

Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities

31 March 2020

1 reference

Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.

31 March 2020

1 reference

N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine

31 March 2020

1 reference

CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases

31 March 2020

1 reference

Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)-roscovitine analogue.

31 March 2020

1 reference

Discovery and evaluation of dual CDK1 and CDK2 inhibitors

31 March 2020

1 reference

The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases

31 March 2020

1 reference

Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor

31 March 2020

1 reference

Specific protection against breast cancers by cyclin D1 ablation

31 March 2020

1 reference

Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis

31 March 2020

1 reference

Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis

31 March 2020

1 reference

Requirement for CDK4 kinase function in breast cancer

31 March 2020

1 reference

Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation

31 March 2020

1 reference

Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues

31 March 2020

1 reference

A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis

31 March 2020

1 reference

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

31 March 2020

1 reference

Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC.

31 March 2020

1 reference

Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1

31 March 2020

1 reference

Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice

31 March 2020

1 reference

Cdk2 knockout mice are viable

31 March 2020

1 reference

Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6

31 March 2020

1 reference

Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia

31 March 2020

1 reference

Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity

31 March 2020

1 reference

Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number

31 March 2020

1 reference

Cdk4 is indispensable for postnatal proliferation of the anterior pituitary.

31 March 2020

1 reference

Failure to proliferate and mitotic arrest of CDK11(p110/p58)-null mutant mice at the blastocyst stage of embryonic cell development

31 March 2020

1 reference

Mice thrive without Cdk4 and Cdk2.

31 March 2020

1 reference

31 March 2020

1 reference

Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM

31 March 2020

1 reference

Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation

31 March 2020

1 reference

Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo

31 March 2020

1 reference

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

31 March 2020

1 reference

Keeping checkpoint kinases in line: new selective inhibitors in clinical trials

31 March 2020

1 reference

Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine

31 March 2020

1 reference

Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.

31 March 2020

1 reference

Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2

31 March 2020

1 reference

Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase.

31 March 2020

1 reference

Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription

31 March 2020

1 reference

Chk1 and Chk2 kinases in checkpoint control and cancer

31 March 2020

1 reference

Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors

31 March 2020

1 reference

Microtubules as a target for anticancer drugs

31 March 2020

1 reference

Polo and Aurora kinases: lessons derived from chemical biology

31 March 2020

1 reference

Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase

31 March 2020

1 reference

AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo

31 March 2020

1 reference

Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts

31 March 2020

1 reference

Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152.

31 March 2020

1 reference

Aurora kinases as anticancer drug targets

31 March 2020

1 reference

Aurora A and B kinases as targets for cancer: will they be selective for tumors?

31 March 2020

1 reference

Molecular basis of drug resistance in aurora kinases

31 March 2020

1 reference

A small-molecule inhibitor of Mps1 blocks the spindle-checkpoint response to a lack of tension on mitotic chromosomes

31 March 2020

1 reference

Ablation of the spindle assembly checkpoint by a compound targeting Mps1.

31 March 2020

1 reference

Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks

31 March 2020

1 reference

Polo-like kinases (Plks) and cancer

31 March 2020

1 reference

Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines

31 March 2020

1 reference

Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals

31 March 2020

1 reference

Normal cells, but not cancer cells, survive severe Plk1 depletion

31 March 2020

1 reference

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

31 March 2020

1 reference

The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1

31 March 2020

1 reference

Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.

31 March 2020

1 reference

Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis

31 March 2020

1 reference

Structure of the catalytic domain of human polo-like kinase 1

31 March 2020

1 reference

A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo

31 March 2020

1 reference

The crystal structure of cyclin A

31 March 2020

2 references

31 March 2020

12 December 2020

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

1 reference

Interaction between the Cdk2/cyclin A complex and a small molecule derived from the pRb2/p130 spacer domain: a theoretical model.

31 March 2020

1 reference

Reaching for high-hanging fruit in drug discovery at protein-protein interfaces

31 March 2020

1 reference

REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors.

31 March 2020

1 reference

Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A.

31 March 2020

1 reference

Lining the pockets of kinases and phosphatases.

31 March 2020

1 reference

Binding of TPX2 to Aurora A alters substrate and inhibitor interactions

31 March 2020

1 reference

Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together

31 March 2020

1 reference

Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization

31 March 2020

1 reference

Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions

31 March 2020

1 reference

Synthetic lethal screen identification of chemosensitizer loci in cancer cells

31 March 2020

1 reference

A quantitative analysis of kinase inhibitor selectivity

31 March 2020

1 reference

The retinoblastoma family: twins or distant cousins?

31 March 2020

1 reference

Critical requirement for cell cycle inhibitors in sustaining nonproliferative states.

31 March 2020

1 reference

Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit

31 March 2020

1 reference

p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F.

31 March 2020

1 reference

p130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activity

31 March 2020

1 reference

A Unique Domain of pRb2/p130 Acts as an Inhibitor of Cdk2 Kinase Activity

31 March 2020

1 reference

Retinoblastoma family proteins: insights gained through genetic manipulation of mice

31 March 2020

1 reference

Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma

31 March 2020

1 reference

Tailoring to RB: tumour suppressor status and therapeutic response

31 March 2020

1 reference

A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy

31 March 2020

1 reference

Cdk11 is a RanGTP-dependent microtubule stabilization factor that regulates spindle assembly rate

31 March 2020

1 reference

CDK11(p58) is required for the maintenance of sister chromatid cohesion

31 March 2020

1 reference

Haploinsufficiency of the cdc2l gene contributes to skin cancer development in mice

31 March 2020

1 reference

Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer

31 March 2020

1 reference

The RB and p53 pathways in cancer

31 March 2020

1 reference

Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation.

31 March 2020

1 reference

Chromosomal passengers: conducting cell division

31 March 2020

1 reference

31 March 2020

1 reference

Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma

31 March 2020

1 reference

Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression

31 March 2020

1 reference

A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer

31 March 2020

1 reference

Characterization of CHEK2 mutations in prostate cancer

31 March 2020

1 reference

Monoallelic BUB1B mutations and defective mitotic-spindle checkpoint in seven families with premature chromatid separation (PCS) syndrome.

31 March 2020

1 reference

Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion

31 March 2020

1 reference

Mechanisms of action of flavopiridol

31 March 2020

1 reference

Flavopiridol in the treatment of chronic lymphocytic leukemia

31 March 2020

1 reference

Synthesis and biological evaluation of N-(7-indolyl)-3-pyridinesulfonamide derivatives as potent antitumor agents.

31 March 2020

1 reference

A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer

31 March 2020

1 reference

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma

31 March 2020

1 reference

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

31 March 2020

1 reference

A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.

31 March 2020

1 reference

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

31 March 2020

1 reference

N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent

31 March 2020

1 reference

P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats

31 March 2020

1 reference

AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis

31 March 2020

1 reference

Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity

31 March 2020

1 reference

Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1.

31 March 2020

1 reference

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

31 March 2020

1 reference

1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.

31 March 2020

1 reference

Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling.

31 March 2020

1 reference

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

31 March 2020

1 reference

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.

31 March 2020

1 reference

A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors.

31 March 2020

1 reference

In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176

31 March 2020

1 reference

Purvalanol A induces apoptosis and downregulation of antiapoptotic proteins through abrogation of phosphorylation of JAK2/STAT3 and RNA polymerase II.

31 March 2020

1 reference

The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor

31 March 2020

1 reference

AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.

31 March 2020

1 reference

1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities

31 March 2020

1 reference

Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells

31 March 2020

1 reference

Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.

31 March 2020

1 reference

Development and biological evaluation of a novel aurora A kinase inhibitor

31 March 2020

1 reference

Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies

31 March 2020

1 reference

Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability

31 March 2020

1 reference

12 December 2020

Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms

1 reference

12 December 2020

Cyclin D-dependent kinases, INK4 inhibitors and cancer

1 reference

12 December 2020

Low rates of aneuploidy promote tumorigenesis while high rates of aneuploidy cause cell death and tumor suppression.

1 reference

12 December 2020

Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability.

1 reference

12 December 2020

HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y

1 reference

12 December 2020

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

1 reference

12 December 2020

The RB family of cell cycle regulatory factors

1 reference

12 December 2020

Inducible pRb2/p130 expression and growth-suppressive mechanisms: evidence of a pRb2/p130, p27Kip1, and cyclin E negative feedback regulatory loop

1 reference

12 December 2020

Terameprocol, a novel site-specific transcription inhibitor with anticancer activity.

1 reference

12 December 2020

Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue

1 reference

12 December 2020

p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107.

1 reference

12 December 2020

Who is the boss in the retinoblastoma family? The point of view of Rb2/p130, the little brother.

1 reference

12 December 2020

The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1

1 reference

12 December 2020

Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer

1 reference

12 December 2020

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours

1 reference

12 December 2020

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

1 reference

12 December 2020

Functional analysis of pRb2/p130 interaction with cyclins

1 reference

12 December 2020

Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth.

1 reference

12 December 2020

[The 2001 Nobel Prize in Physiology or Medicine].

1 reference

12 December 2020